Work

Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials

Year: 2008

Type: article

Abstract: and the American Heart Association make every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional

Source: Circulation

DOI: 10.1161/circulationaha.108.191305

Authors: Jay S. Skyler, Richard Bergenstal, Robert O. Bonow, John Buse, Prakash Deedwania, Edwin A.M. Gale, Barbara V. Howard, M. Sue Kirkman, Mikhail Kosiborod, Peter Reaven, Robert S. Sherwin

Institutions: Northwestern University, University of North Carolina at Chapel Hill, University of Miami, University of California, San Francisco, University of Bristol, VA Central California Health Care System

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: American Diabetes Association, American Heart Association, Park Nicollet Foundation, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Amylin Pharmaceuticals, GlaxoSmithKline, Sanofi, Edwards Lifesciences, Osiris Therapeutics, MannKind Corporation, Halozyme, Dexcom, ResMed, Tandem Diabetes Care, Novo Nordisk, Pfizer Pharmaceuticals, Daiichi Sankyo Europe

OpenAlex ID: W2735325912

FWCI: 23.76

Cites: 18

Cited by: 348

Related to: 10